Bai X J, Chen C X, He Y L
Department of Cardiology, First Affiliated Hospital, China Medical University.
Zhonghua Nei Ke Za Zhi. 1991 Apr;30(4):205-7, 253.
The levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI) and other substances of coagulation-fibrinolysis, such as fibronectin (Fn) and von willebrand factor (vWF) as well as the activity content of antithrombin-III(AT-III) in plasma were determined in 20 patients with acute myocardial infarction (AMI). In 11 of them these measurements were carried out before and after the treatment with urokinase (UK1000 000 IU). The results suggested that the function of coagulation-fibrinolytic system was disturbed in AMI. Thrombolytic treatment with UK could interfere and improve the stabilization of fibrinolytic activity in the body, but these actions last only short time. Some substances of coagulation showed change with UK treatment.
测定了20例急性心肌梗死（AMI）患者血浆中组织型纤溶酶原激活物（t-PA）、纤溶酶原激活物抑制剂（PAI）以及其他凝血-纤溶物质，如纤连蛋白（Fn）和血管性血友病因子（vWF）的水平，同时还测定了抗凝血酶Ⅲ（AT-Ⅲ）的活性含量。其中11例患者在接受尿激酶（UK 1000 000 IU）治疗前后进行了上述测定。结果提示，AMI患者凝血-纤溶系统功能紊乱。尿激酶溶栓治疗可干扰并改善体内纤溶活性的稳定，但这些作用仅持续较短时间。一些凝血物质在尿激酶治疗后出现了变化。
